Can Fite Biopharma CANF.TA · ILA

Its shares trade on Tel Aviv under the ticker CANF.TA. It has been listed since 22 September 2005. In the fiscal year to 31 December 2025, it reported revenue of $438,400 and a net loss of $10.6m. At that date it held total assets of $9.5m and shareholders' equity of $5.6m.

Can-Fite BioPharma Ltd. engages in the development of drugs for cancer and inflammatory diseases. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Ilan CohenChairman of the Board, since 1994ILS 339,000
• Dr. Pnina FishmanChief Executive Officer, Director, since 1994$767,000
• Mr. Motti FarbsteinChief Financial Officer, Chief Operating Officer$484,000
• Dr. Sari FishmanVice President - Business Development$380,000
• Mr. Yoseph BorensteinDirector
• Mr. Yaacov GoldmanIndependent Director$43,000
• Mr. Guy RegevIndependent Director$43,000
• Dr. Abraham SartaniIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.